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Abstract 
Background: Toxoplasma gondii is the most common parasite causing latent cerebral 
infections in human. It has been shown that some anti-psychotic drugs are able to 
inhibit the proliferation of the parasite in in vitro study. There is very limited data 
regarding the inhibitory effect of anti-psychotics on Toxoplasma in in vivo. In this 
study, we evaluated anti-Toxoplasma activity of fluphenazine and thioridazine drugs 
on T. gondii in mice.  
Methods: Mice were divided into six groups: Control, sesame as vehicle, thiori-
dazine 10 mg/kg, thioridazine 20 mg/kg, fluphenazine 0.06 mg/kg and fluphena-
zine 0.6 mg/kg. They were inoculated intraperitoneally with brain suspension con-
taining tissue cysts of T. gondii Tehran strain. Two months after inoculation, the 
number of cysts in crushed smears of mice brain were counted microscopically and 
considered as an indicator of anti-Toxoplasma activity. This work has conducted in 
Qazvin, central Iran, 2014. 
Results: Our study showed that fluphenazine and thioridazine could not signifi-
cantly inhibit the brain cystogenesis of T. gondii in mice. However, the number of 
brain cysts was less at higher dose compared to lower doses for both drugs.  
Conclusion: Further studies need to clear the mechanism of different structure of 
anti-psychotic drugs on activity of Toxoplasma. 
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Introduction 
 
oxoplasma gondii is an obligatory intra-
cellular protozoan with worldwide 
distribution. At least, 20% of popula-
tions are seropositive for anti- T. gondii anti-
bodies in most of developing countries (1), 
and usually 10%-20% in developed countries 
(2). Due to long-life persistence of brain T. 
gondii infections, the parasite is suspected as 
one of the possible causative agents of some 
of chronic neurologic disorders, particular of 
schizophrenia (3). There are different epide-
miological and experimental evidences that 
support the role of T. gondii in developing of 
chronic mental disorders and behavioral alter-
ations. These evidences have been reviewed 
by some of Toxoplasma researchers in recent 
years (4, 5). The most of evidences is related 
to schizophrenia, so that at least 40 papers 
reported increased seroprevalence of anti-
Toxoplasma antibodies in schizophrenic pa-
tients with the significant differences in the 
most of cases (6-8).  
Experimentally, there are evidences that 
strengthen probable role of latent T. gondii in-
fections on the behavior of laboratory animals, 
for examples, prolongation of reaction times 
in mice (9), the loss of the fear response to cat 
odor (10), and decreasing of neophobic be-
havior (11). Morphologically, there are evi-
dences that T. gondii infections can induce 
morphological changes in brain of subjects 
genetically predisposed. Horacek et al. report-
ed reduction of gray matter density in Toxo-
plasma infected patients (12).  
One of the most important evidences that 
supported the role of T. gondii in developing of 
psychotic disorders is related to effect of anti-
psychotic drugs on it. The replication of T. 
gondii RH strain tachyzoites is inhibited by 
valproic acid (a mood stabilizer drug) in cell 
culture (13). This drug is able to retain innate 
avoidance of cat odor in rats infected with T. 
gondii (14). In addition, it had no protective 
effect on mice inoculated with a virulent RH 
strain tachyzoites, and was inactive on brain 
cysts in mice inoculated with an avirulent 
ME49 strain of the parasite (15). Proliferation 
of the RH strain tachyzoites could be inhibited 
by anti-psychotic agents including, fluphena-
zine, thioridazine, and trifluoperazine (16), but 
there is no report in respect of inhibition of 
cystogenesis of the parasite in treated mice 
with these drugs.  
In this study, we evaluated the inhibitory ac-
tivity of fluphenazine and thioridazine on T. 
gondii in mice.  
 
Materials and Methods 
 
Drugs 
Thioridazine was prepared from Pars Minoo 
Industrial Co. and fluphenzazine decanoate 
was purchased from Chemidarou Pharmaceu-
tical Co., Iran in injectable form. Thioridazine 
was dissolved in saline. Sesame oil was used 
for dilution and preparing suitable concentra-
tion of it. Other drugs in this investigation 
were xylazine (Loughrea, Co. Galway, Ireland) 
and ketamine (Rotexmedica, GmbH, Germa-
ny), which used for anesthesia of mice. All 
drugs were administrated intraperitoneally (ip). 
 
Animals 
Sixty tree male BALB/c mice (20–25 g) were 
obtained from the Razi Institute (Karaj, Iran, 
2014) and housed in groups of four per cage 
under standard laboratory conditions. They 
were kept at a constant room temperature (21 
± 2 °C) under a normal 12L: 12D regimen 
with free access to food and water. All animal 
experiments were carried out in accordance 
with the European Communities Council Di-
rective of 24 November 1986 (86/609/EEC) 
in such a way as to minimize the number of 
animals and their suffering. 
 
Treatment procedure 
Before treatment of mice with the anti-
schizophrenic agents, they were examined by 
T 
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Sabin-Feldman dye test (17) for anti-T. gondii 
antibodies in order to prove to be devoid of 
previous infection with T. gondii. Mice were 
divided into six groups: Control (n=11), sesa-
me as vehicle (n=10), thioridazine 10 mg/kg 
(n=10), thioridazine 20 mg/kg (n=10), 
fluphenazine 0.06 mg/kg (n=11) and fluphen-
azine 0.6 mg/kg (n=11). The selected doses of 
both drugs were based of previous animal 
studies that they have been used as anti-
psychotic drugs. Then, these doses were not 
toxic for them. 
Mice were inoculated intraperitoneally with 
brain suspension of mice which two months 
earlier had been infected with tissue cysts of T. 
gondii Tehran strain. A half mile litter of the 
brain suspension in sterile saline containing 
approximately 20 tissue cysts was inoculated 
to each of mice in all of the groups. Sesame 
and drugs were injected three days after inocu-
lation of parasites, every other day for three 
weeks. Control mice did not receive any drugs. 
At the end of second month after inocula-
tion, the mice were anesthetized with intraper-
itoneal injections of ketamine/xylazine (60 
mg/kg and 6 mg/kg, respectively). Mice were 
sacriﬁced under anesthesia, and their brains 
were quickly removed. Then, crushed smears 
were separately provided from whole brain of 
each mouse. The number of tissue cysts was 
counted with optical microscope with magni-
fication 100 and 400. The frequency differ-
ence of the number of brain cysts between 
cases and controls mice was considered as in-
hibition index. 
 
Statistical analysis 
For normalizing the initial data, natural loga-
rithm transformation was used. In data analysis, 
Kolmogorov-Smirnov test, Analysis of Variance 
(ANOVA) and Tukey Post-Hoc were used. A 
level of P < 0.05 was considered signiﬁcant. 
 
Results 
 
Before inoculation of the parasite, all of the 
mice were seronegative for anti-Toxoplasma 
antibodies by Sabin-Feldman dye test. Some 
of the animal died in different weeks after in-
oculation before ending the experiments. The 
tissue cysts were formed in brain of all of mice, 
and the means number of brain cysts in the 
sesame group were higher than control group. 
However, this difference was not significant 
(Fig. 1). There was no different between the 
number of cysts at the two doses of thiori-
dazine compared to control group (P> 0.05) 
(Fig. 1). Furthermore, there was no difference 
between the number of cysts of two doses of 
fluphenazine compared to control and sesame 
groups (Fig. 1). 
 
 
 
Fig. 1: Number of brain cysts (in Logarithm) of T. 
gondii (mean± SEM) in each treated and control 
mice groups 
 
Discussion 
 
Our study showed that thioridazine and 
fluphenazine could not inhibit T. gondii in mice. 
These results of in vivo have a conflict with in 
vitro results of Goodwin and colleagues, who 
have reported that thioridazine and fluphena-
zine (IC50 of 1.7, 1.2 µM, respectively) inhibit-
ed proliferation of T. gondii tachyzoites in in 
vitro study (16). Similarly, in the previous 
studies, the difference between the pattern of 
inhibitory effects of mood stabilizer valproic 
acid on Toxopalasma in in vitro and in in vivo 
studies has been reported (14, 15, 18). Valpro-
ic acid is active against tachyzoites of T. gondii 
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with two variable concentrations in in vitro 
assays. This difference might be related to 
their different test system (13, 18). However, 
valproic acid was not active against acute and 
chronic infections of T. gondii in mice (15).  
On the other hand, in the clinical trial stud-
ies, treatment of schizophrenic patients with 
anti-toxoplasmosis drugs trimethoprim (19) 
and azithromycin (20) could not significantly 
improve the symptom of disease. This diversi-
ty of responses may be related to different ef-
ficacy of drugs in in vitro and in vivo condi-
tions. Pharmacokinetic properties of drug in-
cluding absorption, distribution, metabolism, 
and elimination are considered as a biological 
profile in in vivo models (21).  
It seems that our study compared to Good-
win et al. provides a supporting evidence to 
confirm that anti-psychotic drugs have not 
inhibitory effects on tachyzoites proliferation 
of T. gondii in in vivo. Since, we injected thior-
idazine and fluphenazine in acute phase of 
infection in mice. However, they orally admin-
istrated valproic acid eight weeks after inocula-
tion T. gondii (in latent phase) (15). Tachyzoites 
of T. gondii proliferates inside host cells in the 
acute phase of infection. Then, the invasion 
and proliferation will be usually inhibited with-
in less than a month and afterward, the 
tachyzoites convert to bradyzoites enclosed in 
tissue cysts that can be maintained in host tis-
sue for long time as a chronic infection. Drugs 
that are used for treatment of toxoplasmosis, 
are effective on tachyzoites not tissue cysts.  
In this study, hypothesis of inhibitory effect 
of fluphenazine and thioridazine on Toxoplas-
ma was not established in mice. However, this 
finding certainly did not rebut possible role of 
the parasite in occurrence of chronic brain 
diseases especially schizophrenia. If the para-
site is considered as one of the possible causa-
tive agents of schizophrenia, then, it will be 
prospected that T. gondii is caused schizophre-
nia only in some of infected individuals with 
the parasite. Since, the prevalence of T. gondii 
is much more than schizophrenia in general 
population. So that one third of the world's 
population was infected to T. gondii (4), but 
lifetime prevalence of schizophrenia is about 
1% (22).  
The mechanism of anti-toxoplasmosis drugs 
is established. However, this mechanism about 
antipsychotic drugs is unclear. The typical an-
ti-psychotic agents block D2 receptors stereo 
selectively for the most part of the brain, and 
their binding affinity is very strongly correlat-
ed with clinical anti-psychotic potency (23). In 
this study, we have used typical anti-psychotic 
drugs fluphenazine and thioridazine that block 
D2 receptors in the brain. An increase in in-
tracellular calcium occurs in tachyzoites of T. 
gondii when they attach to their host cells and 
this increase is required for invasion. Initial 
attachment of tachyzoites to host cells is fol-
lowed by calcium signaling (24) and this inter-
action was inhibited by calcium channel 
blockers (verapamil) and calmodulin antago-
nists such as trifluoperazine and calmidazoli-
um (25). It seems that calmodulin is located in 
anterior portion of T. gondii tachyzoites, which 
might be related to host cell invasion (26) and 
it is possible by mediating calcium-dependent 
conoid extrusion and through calcium-
stimulated secretion of lytic enzymes at the 
adhesion site on the host cell membrane caus-
es to fluidize it and facilitate entry of parasite 
(16). Nevertheless, we did not find this effect 
significantly. 
Another issue that should be mentioned in 
this study is that we have selected two doses 
of both fluphenazine and thioridazine less 
than LD50. Since, increasing dose more than it 
was impractical. Furthermore, in these select-
ed doses, some mortality was happen that 
might be related to the difference between 
drugs and doses of them. 
 
Conclusion 
 
Fluphenzazine and thioridazine could not 
significantly inhibit the brain cystogenesis of T. 
gondii in mice. However, each of them reduced 
the percent of cysts at higher dose compared 
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to lower doses. However, these effects were 
not significant. 
 
Acknowledgments 
 
The authors are kindly appreciate Dr. H. 
Keshavarz, and Dr. S. Shojaee, Department of 
Parasitology and Mycology, School of Public 
Health, Tehran University of Medical Sciences 
for preparing an avirulent Tehran strain of T. 
gondii. The authors are thankful to the Vice 
Chancellor of Research, Qazvin University of 
Medical Sciences, for financial support. The 
results described in this article are part of an 
MSc thesis of Y. Ghaderi. The authors declare 
that there is no conflict of interest. 
 
References 
 
1. Daryani A, Sarvi S, Aarabi M, Mizani A, Ah-
madpour E, Shokri A, et al. Seroprevalence of 
Toxoplasma gondii in the Iranian general popula-
tion: A systematic review and meta-analysis. 
Acta Trop. 2014; 137: 185-194.  
2. Jones JL, Kruszon-Moran D, Rivera HN, Price 
C, Wilkins PP. Toxoplasma gondii seroprevalence 
in the United States 2009-2010 and comparison 
with the past two decades. Am J Trop Med 
Hyg. 2014; 90(6):1135-1139. 
3. Yolken RH, Dickerson FB, Fuller Torrey E. 
Toxoplasma and schizophrenia. Parasite Immu-
nol. 2009; 31(11):706-715.  
4. Flegr J. Influence of latent Toxoplasma infection 
on human personality, physiology and mor-
phology: pros and cons of the Toxoplasma-
human model in studying the manipulation hy-
pothesis. J Exp Biol. 2013; 216 (Pt 1):127-133.  
5. McConkey GA, Martin HL, Bristow GC, 
Webster JP. Toxoplasma gondii infection and be-
haviour - location, location, location? J Exp Bi-
ol. 2013; 216 (Pt 1):113-119. 
6. Torrey EF, Bartko JJ, Lun ZR, Yolken RH. 
Antibodies to Toxoplasma gondii in patients with 
schizophrenia: a meta-analysis. Schizophr Bull. 
2007; 33(3):729-736. 
7. Park MH, Kwon YJ, Jeong HY, Lee HY, 
Hwangbo Y, Yoon HJ, et al. Association be-
tween intracellular infectious agents and schiz-
ophrenia. Clin Psychopharmacol Neurosci. 
2012; 10(2):117-123. 
8. Alipour A, Shojaee S, Mohebali M, Teh-
ranidoost M, Abdi Masoleh F, Keshavarz H. 
Toxoplasma infection in schizophrenia patients: 
a comparative study with control group. Iran J 
Parasitol. 2011; 6(2), 31-37.  
9. Hrdá S, Votýpka J, Kodym P, Flegr J. Transi-
ent nature of Toxoplasma gondii-induced behav-
ioral changes in mice. J Parasitol. 2000; 86(4), 
657-663. 
10. Berdoy M, Webster JP, Macdonald DW. Fatal 
attraction in rats infected with Toxoplasma gondii. 
Proc Biol Sci. 2000; 267(1452): 1591-1594. 
11. Webster JP, Brunton CF, MacDonald DW. 
Effect of Toxoplasma gondii upon neophobic 
behavior in wild brown rats, Rattus norvegicus. 
Parasitology. 1994;109(Pt 1): 37-43 
12. Horacek J, Flegr J, Tintera J, Verebova K, 
Spaniel F, Novak T, et al. Latent toxoplasmosis 
reduces gray matter density in schizophrenia 
but not in controls: voxel-based-morphometry 
(VBM) study. World J Biol Psychiatr. 2012; 
13(7):501-509. 
13. Jones-Brando, Torrey EF, Yolken R. Drugs 
used in the treatment of schizophrenia and bi-
polar disorder inhibit the replication of Toxo-
plasma gondii. Schizophr Res. 2003; 62(3):237-
244. 
14. Webster JP, Lamberton PH, Donnelly CA, 
Torrey EF. Parasites as causative agents of 
human affective disorders? The impact of anti-
psychotic, mood-stabilizer and anti-parasite 
medication on Toxoplasma gondii's ability to alter 
host behaviour. Proc Biol Sci. 2006; 273(1589): 
1023-1030. 
15. Goodwin DG, Strobl J, Mitchell SM, Zajac 
AM, Lindsay DS. Evaluation of the mood-
stabilizing agent valproic acid as a preventative 
for toxoplasmosis in mice and activity against 
tissue cysts in mice. J Parasitol. 2008; 94(2):555-
557.  
16. Goodwin DG, Strobl JS, Lindsay DS. Evalua-
tion of five antischizophrenic agents against 
Toxoplasma gondii in human cell cultures. J Para-
sitol. 2011; 97(1):148-151. 
17. Johanson JS, Holliman RE. Toxoplasmosis. In: 
Gillespie SH, Hawkey PM, editors. Medical 
parasitology a practical approach. New York: 
Oxford University Press Inc; 1995, p. 33-59. 
Saraei et al.: The Effect of Fluphenazine and Thioridazine … 
Available at: http://ijpa.tums.ac.ir                                                                                                231 
18. Strobl JS, Cassell M, Mitchell SM, Reilly CM, 
Lindsay DS. Scriptaid and suberoylanilide hy-
droxamic acid are histone deacetylase inhibitors 
with potent anti-Toxoplasma gondii activity in vitro. 
J Parasitol. 2007; 93(3): 694-700. 
19. Shibre T, Alem A, Abdulahi A, Araya M, Bey-
ero T, Medhin G, et al. Trimethoprim as adju-
vant treatment in schizophrenia: a double-blind, 
randomized, placebo-controlled clinical trial. 
Schizophr Bull. 2010; 36(4): 846-851. 
20. Dickerson FB, Stallings CR, Boronow JJ, Ori-
goni AE, Yolken RH. A double-blind trial of 
adjunctive azithromycin in individuals with 
schizophrenia who are seropositive for Toxo-
plasma gondii. Schizophr Res. 2009; 112(1-
3):198-199.  
21. Carroll FI, Houghten RA. From rapid in vitro 
screening to rapid in vivo screening in the drug 
discovery process. Neuropsychopharmacology. 
2009; 34(1):251-252.  
22. Walker E, Kestler L, Bollini A, Hochman KM. 
Schizophrenia: Etiology and course. Annu Rev 
Psychol. 2004; 55:401-430. 
23. Meltzer H. Antipsychotic Agents and Lithium. 
In: Katzung BG, Masters SB, Trevor AJ editors. 
Basic and clinical pharmacology. New York: 
McGraw-Hill; 2012, p. 362-383. 
24. Vieira MC, Moreno SN. Mobilization of intra-
cellular calcium upon attachment of Toxoplasma 
gondii tachyzoites to human fibroblasts is re-
quired for invasion. Mol Biochem Parasitol. 
2000; 106(1):157-162. 
25. Pezzella N, Bouchot A, Bonhomme A, Pingret 
L, Klein C, Burlet H, et al. Involvement of cal-
cium and calmodulin in Toxoplasma gondii 
tachyzoite invasion. Eur J Cell Biol. 1997; 74(1): 
92-101. 
26. Song HO, Ahn MH, Ryu JS, Min DY, Joo KH, 
Lee YH. Influence of calcium ion on host cell 
invasion and intracellular replication by Toxo-
plasma gondii. Korean J Parasitol. 2004; 
42(4):185-193. 
 
Reproduced with permission of the copyright owner. Further reproduction prohibited without
permission.
